Ajai Chari
Great Ormond Street Hospital(GB)University College London(GB)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Teclistamab in Relapsed or Refractory Multiple Myeloma(2022)1,022 cited
- → Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial(2016)843 cited
- → Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study(2019)777 cited
- → Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma(2019)662 cited
- → Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial(2020)660 cited
- → Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma(2022)599 cited
- → B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches(2020)474 cited
- → Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma(2017)441 cited
- → Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma(2016)403 cited
- → Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study(2021)298 cited